Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma

The immunomodulatory agent pomalidomide (POM) plus dexamethasone (DEX) is approved in the United States and European Union for patients with relapsed or refractory multiple myeloma (RRMM), including those with renal impairment (RI). MM-013, a phase 2, noncomparative trial (NCT02045017; EudraCT No. 2013-001903-36), has shown a benefit with POM + DEX in patients with severe RI, including those requiring hemodialysis, and moderate RI (Dimopoulos M, et al. J Clin Oncol. 2018;36:2035-2043). Here, we report the efficacy and safety of POM + DEX treatment (Tx) for ≥ 1 year.